Liquidia Corporation (LQDA)

Market Cap	3.42B +169.9%
Revenue (ttm)	158.32M +1,031.2%
Net Income	-68.92M
EPS	-0.80
Shares Out	88.11M
PE Ratio	n/a
Forward PE	16.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	697,665
Open	38.20
Previous Close	38.55
Day's Range	37.55 - 39.01
52-Week Range	11.85 - 46.67
Beta	0.46
Analysts	Strong Buy
Price Target	41.00 (+5.53%)
Earnings Date	May 7, 2026

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L6...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 26, 2018
• Employees: 216
• Stock Exchange: NASDAQ
• Ticker Symbol: LQDA
• Website: https://www.liquidia.com

Financial Performance

In 2025, Liquidia's revenue was $158.32 million, an increase of 1031.18% compared to the previous year's $14.00 million. Losses were -$68.92 million, -46.28% less than in 2024.

Analyst Summary

According to 11 analysts, the average rating for LQDA stock is "Strong Buy." The 12-month stock price target is $41.0, which is an increase of 5.53% from the latest price.

Price Target

$41.0

(5.53% upside)

Analyst Consensus: Strong Buy